Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of MgIG (magnesium isoglycyrrhizinate) in preparing treatment drug for relieving renal injury caused by aminoglycoside antibiotics

A technology of aminoglycosides and magnesium isoglycyrrhizinate, applied in the field of natural medicine

Inactive Publication Date: 2017-10-24
CHINA PHARM UNIV
View PDF3 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the side effects restricting the widespread use of this type of drug are serious nephrotoxicity and irreversible ototoxicity.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of MgIG (magnesium isoglycyrrhizinate) in preparing treatment drug for relieving renal injury caused by aminoglycoside antibiotics
  • Application of MgIG (magnesium isoglycyrrhizinate) in preparing treatment drug for relieving renal injury caused by aminoglycoside antibiotics
  • Application of MgIG (magnesium isoglycyrrhizinate) in preparing treatment drug for relieving renal injury caused by aminoglycoside antibiotics

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0013] Example 1: Determination of renal function-related biochemical indicators in SD rats after multiple administrations

[0014] The main steps are as follows:

[0015] Thirty-six male SD rats were randomly divided into six groups according to body weight, with 6 rats in each group.

[0016] 1. Protective effect of magnesium isoglycyrrhizinate on gentamicin-induced renal injury model: gentamicin combined with magnesium isoglycyrrhizinate medication group: SD rats were pre-administered magnesium isoglycyrrhizinate for 5 days (i.p 50mg / kg / day), starting from the 6th day, magnesium isoglycyrrhizinate was given Half an hour after the medicine, 70 mg / kg gentamicin was administered intraperitoneally (i.p.) for 7 consecutive days. Gentamicin alone group: During the pre-administration period of magnesium isoglycyrrhizinate, an equal volume of normal saline was injected intraperitoneally every day, and from the 6th day, 70 mg / kg gentamicin was administered intraperitoneally (i.p.) ...

Embodiment 2

[0020] Embodiment 2: Kidney histopathological examination after repeated administration of SD rats

[0021] The main steps are as follows:

[0022] The aminoglycoside drug-induced kidney injury model establishment method and dosage regimen are the same as in Example 1. The rats were sacrificed 4 hours after administration on the last day, and the left kidney was cut longitudinally, half of which was fixed with 4% paraformaldehyde for histopathological detection (HE / PAS staining).

[0023] Experimental results:

[0024] Pathological examination results such as figure 2shown. In the gentamicin (GM)-induced renal injury model group and the amikacin (AMK)-induced renal injury model group, tubular necrosis in the renal cortex area, dilated renal tubules, increased basophilic renal tubules, interstitial Inflammatory cell infiltration was more severe than that in the blank control group; under the PAS staining microscope, the brush border of the renal proximal tubule was obvious...

Embodiment 3

[0025] Example 3: Expression of mRNA levels of mitochondrial bioremediation regulatory factors in kidney tissue of SD rats after multiple administrations

[0026] The main steps are as follows:

[0027] The aminoglycoside drug-induced kidney injury model establishment method and dosage regimen are the same as in Example 1. The rats were sacrificed 4 hours after administration on the last day, and half of the left kidney was cut longitudinally. Kidney tissue RNA was extracted according to the Takara total RNA extraction kit, and the RNA was quantified. According to the instructions of the RT-PCR kit, the mRNA was reverse transcribed into cDNA. Real-time fluorescent quantitative PCR analysis was performed according to the instructions of Thermal Cycler DiceTM RealTime System (TakaRa Code: TP800). The expression of mRNA levels of mitochondrial biorepair regulators in kidney tissue: peroxisome proliferator-activated receptor gamma coactivator 1α (PGC-1α) and nuclear respiratory...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the field of natural drugs, in particular to an application of MgIG (magnesium isoglycyrrhizinate) in preparing a drug for reducing renal toxicity caused by aminoglycoside antibiotics. The concentration of aminoglycoside drugs in tissue of SD rats can be reduced when MgIG and aminoglycoside antibiotics (gentamicin and amikacin) are combined for use, the renal toxicity caused by aminoglycoside antibiotics is resisted, the renal function is improved, the antibacterial activity of gentamicin is not affected, and accordingly, MgIG can serve as a renal protection drug of the aminoglycoside antibiotics for combined use.

Description

technical field [0001] The invention relates to the field of natural medicines, in particular to the application of magnesium isoglycyrrhizinate in the preparation of therapeutic drugs for improving kidney damage caused by aminoglycoside antibiotics. Background technique [0002] Infectious diseases have always been one of the diseases that pose a great threat to human health. Epidemiological statistics show that infectious diseases cause tens of millions of deaths every year, accounting for one-third of the global annual death toll; the global market sales of anti-infective drugs are nearly 100 billion U.S. dollars, accounting for about 10%, and an annual growth rate of not less than 8%; while my country is the country with the largest sales of anti-infective drugs in the world, and this demand will further increase with the increase in the number of drug users. However, due to the abuse of anti-infective drugs and the lack of new anti-infective drugs, bacterial resistance ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/704A61K31/7036A61P13/12A61P31/04
CPCA61K31/7036A61K31/704A61K2300/00
Inventor 王广基周芳蔡名敏
Owner CHINA PHARM UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com